Market capitalization | $7.96m |
Enterprise Value | $-940.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.04 |
P/B ratio (TTM) P/B ratio | 1.06 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-28.92m |
Free Cash Flow (TTM) Free Cash Flow | $-24.28m |
Cash position | $9.41m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Moleculin Biotech, Inc. forecast:
2 Analysts have issued a Moleculin Biotech, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
43%
43%
|
|
EBITDA | -29 -29 |
5%
5%
|
EBIT (Operating Income) EBIT | -29 -29 |
4%
4%
|
Net Profit | -30 -30 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
Head office | United States |
CEO | Walter Klemp |
Employees | 18 |
Founded | 2015 |
Website | www.moleculin.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.